- StocksGeniusMastery
- Posts
- 💥Eli Lilly Just Won Approval for Foundayo — Is the Stock Ready for Another Run?
💥Eli Lilly Just Won Approval for Foundayo — Is the Stock Ready for Another Run?
The next phase of GLP-1 growth could extend far beyond what Zepbound already achieved.
Bensheares Parker
April 13, 2026
In partnership with
Hi Fellow Investors,
Eli Lilly and Company (NYSE: LLY) continues to strengthen one of the most powerful growth franchises in global healthcare, and regulatory approval for Foundayo may broaden that momentum even further.
The company already dominates key segments of GLP-1 demand, but an oral option now creates an entirely new expansion path.
Key Points:
Foundayo gives Eli Lilly access to patients who prefer pills over injectable treatments.
Existing GLP-1 products are already producing extraordinary revenue growth.
Valuation remains elevated, but long-term pipeline strength continues supporting the premium.
TODAY’S SPONSOR
The ones showing up in LLMs convert 3× better than Google
They optimized for LLMs, not just Google.
FAQs. Comparison pages. Transparent pricing. LinkedIn presence. These aren't vanity plays. They're what gets you cited in ChatGPT, Gemini, and Claude when your buyers are researching, your investors are looking, and your future hires are deciding where to work.
Download the free AEO Playbook for Startups from HubSpot and get the exact checklist. Five minutes to read.
Why Foundayo Could Expand Eli Lilly’s Reach Significantly
Foundayo matters because convenience changes patient adoption.
Many patients who hesitate around injections are far more likely to consider a pill-based therapy.
That creates access to a broader treatment population beyond current injectable demand.
The oral format may also improve adherence for certain patients over time.
For Eli Lilly, this expands both volume potential and competitive reach.
GLP-1 Growth Is Already Transforming Eli Lilly’s Revenue Base
The company’s recent revenue growth has already been extraordinary.
Annual revenue rose 45% to $65.2 billion.
Zepbound generated $13.5 billion and grew 175% year over year.
Mounjaro nearly doubled revenue to just under $23 billion.
That means Eli Lilly enters the pill phase from an already dominant position.
Why the Stock Has Not Fully Reacted Yet
Despite approval, the stock has not surged dramatically.
One reason is valuation.
The shares still trade above 40 times trailing earnings, which keeps some investors cautious.
Even strong catalysts sometimes struggle to move premium stocks immediately.
Markets often wait for early prescription data before rewarding new approvals.
Why Long-Term Investors Still See Strong Upside
Eli Lilly’s strength extends beyond one product.
Its broader late-stage pipeline remains unusually deep.
That gives the company multiple growth engines beyond GLP-1 therapies.
When a dominant franchise also has pipeline depth, valuation often remains elevated for longer than expected.
This is why many long-term investors remain constructive despite short-term hesitation.
Strengths
Eli Lilly controls one of the most powerful growth franchises in modern pharmaceuticals.
Foundayo expands access to a much broader weight-loss patient base.
Existing GLP-1 products continue delivering exceptional revenue acceleration.
Weaknesses
Premium valuation creates hesitation for investors seeking immediate upside.
Market expectations are already extremely high after years of outperformance.
Early pill adoption data will matter before confidence fully expands.
Potential
Oral GLP-1 adoption could significantly increase total addressable demand.
Pipeline depth gives Eli Lilly multiple future catalysts beyond obesity.
If Foundayo scales quickly, earnings estimates may move higher again.
TODAY’S SPONSOR
Are you tracking agent views on your docs?
AI agents already outnumber human visitors to your docs — now you can track them.
Conclusion
Foundayo strengthens an already dominant growth story rather than creating one from scratch.
Eli Lilly now has both injectable leadership and oral expansion potential inside the same therapeutic wave.
That combination remains unusually powerful for long-term healthcare investors.
Final Thought
The strongest pharmaceutical franchises often become even more valuable when convenience expands access.
For Eli Lilly, the next phase of GLP-1 may now be less about invention and more about scale.
Can I ask a small favor from you if you find the content useful to you? Spread the wealth by sharing my FREE Newsletter with fellow stock investors and friends and help to check out my sponsor advertisement and that will keep me writing more stocks newsletters!
Of course, you should always do your own research and due diligence before investing in any stock. You should also diversify your portfolio and balance your risk and reward too!
~ Final Thought: "Fortune Favors the Bold: Embrace Opportunity Property, Execute Strategy, and Reap the Rewards of Investing Wisely.”🌱
What's Your Take on Our Newsletter? 🌟We're eager to hear your thoughts so we can make our newsletter even more amazing for you! |
Disclaimer: The content provided on this blog is for educational and informational purposes only and is not intended as financial, investment, tax, or legal advice. Investing in the stock market involves risks, including the loss of principal. The views, thoughts, and opinions expressed in this blog are solely those of the author and do not reflect the views of any company, organization, or other group. Readers are encouraged to perform their own research and due diligence before making any financial decisions and actions based on the content. Neither the author nor the publisher is liable for any losses or damages arising from the use of the advice or information contained herein.
Reply